Virax Biolabs Shares Soar 240% After Fosun Multi-Country Supply Pact
VRAX•VRAX•VRAX•VRAX•Virax Biolabs shares climbed 240.25% to $10.82 after it inked an exclusive multi-country supply and distribution agreement with Fosun. The deal grants Fosun exclusive rights to distribute Virax’s virology products across multiple markets, significantly expanding the company’s regional commercial footprint.
Virax Biolabs has entered into an exclusive multi-country supply and distribution agreement with Fosun, granting Fosun sole rights to market and distribute Virax’s virology product portfolio across multiple territories. The pact is designed to accelerate commercialization and broaden Virax’s market reach in key regions.
Following the announcement, Virax Biolabs shares surged 240.25% to close at $10.82 on heavy trading volume. The sharp rally reflects investor enthusiasm over the expanded commercial prospects and potential revenue growth from the new partnership.
